Eric Vachon on the Effect of Complexity on Adherence with Kinase Inhibitors

Video

Eric Vachon, BSN, PhD candidate, discusses the importance of taking all variables of complexity into account when considering adherence to kinase inhibitors.

Eric Vachon, BSN, PhD candidate, Michigan State University, discusses the many variables of complexity that can effect adherence to kinase inhibitors.

The regimen for kinase inhibitors is the most complex. Many current studies focus only on the issue of continuous versus cycling. However, there are other considerations that Vachon is studying in his own research.

Recent Videos
Image of a woman with a white shirt in front of an Oncology Nursing News branded backdrop
Managing Oncology Nurse Burnout Through Peer Support, Emotional Intelligence
Bridging Communication Gaps: Comprehensive Care for Upper GI Cancer Treatment
Bridging Communication Gaps: Comprehensive Care for Upper GI Cancer Treatment
Multidisciplinary Collaboration in Managing Treatment-Related AEs in Upper GI Cancer
Multidisciplinary Collaboration in Managing Treatment-Related AEs in Upper GI Cancer
Managing Symptoms and Quality of Life During HER2-Targeted Therapy for Upper GI Cancer
Managing Symptoms and Quality of Life During HER2-Targeted Therapy for Upper GI Cancer
Photo of a man with glasses in a suit in front of an Oncology Nursing News backdrop
Supporting Patients Through New Breast Cancer Treatments
Image of Jessie Desir, PhD, RN, AMB-BC, OCN, in a video call with a blue and gold Oncology Nursing News border surrounding the frame.
Patient Education Is Key to Improve Patient Adherence to Cancer Treatment
5 experts in this video
Treatment Goals, Side Effects, and Supportive Care Strategies for Patients and Caregivers with HER2+ BC
5 experts in this video
Supporting HER2+ mBC Patients in Later Lines: AE Management and the Role of the Multidisciplinary Team
Screen capture of Seth Eisenberg, ASN, RN, OCN, BMTCN, on a video call with an Oncology Nursing News branded border around the frame
Toilet Cover May Significantly Reduce Aerosol Exposure in Hospital Bathrooms
Managing Adverse Events With Trastuzumab Deruxtecan: Early Detection and ILD Monitoring Strategies
Managing Adverse Events With Trastuzumab Deruxtecan: Early Detection and ILD Monitoring Strategies
Related Content
Side profile anatomical rendering of a person, with breast tissue and a breast tumor in orange

Vepdegestrant Meets PFS End Point for Metastatic Breast Cancer Subtype

Ashley Chan
March 25th 2025
Article
Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Lindsay Fischer
October 2nd 2023
Podcast

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

Illustration of small patient and provider characters surrounded by larger technology devices with medical information coming off of the screens and other medical props nearby

Mobile App May Be Feasible for Tracking Oral Cancer Medication Adherence

Bridget Hoyt
March 10th 2025
Article

Although participants in the study had greater rates of nonadherence postintervention, those who reported nonadherence at baseline saw some increase in adherence.

The Vitals

Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

Lindsay Fischer
January 16th 2023
Podcast

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.

Blue rendering of a person with breast tissue highlighted in orange

T-DM1 Further Improves DFS and OS vs Trastuzumab in HER2-Positive Early Breast Cancer

Bridget Hoyt
February 20th 2025
Article

T-DM1 reduced risk of invasive disease events and death compared with trastuzumab in HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy.

Blue image of a breast with tissue and a tumor highlighted in orange

KN026-Docetaxel Combo Shows Efficacy, Safety in HER2+ Metastatic Breast Cancer

Ashling Wahner
February 17th 2025
Article

Patients with recurrent/metastatic HER2-positive breast cancer experienced durable response and manageable safety from KN026-docetaxel combination therapy.